VEGF inhibitor (monoclonal antibody)

This page covers all VEGF inhibitor (monoclonal antibody) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF (Vascular Endothelial Growth Factor), VEGF-A, VEGF-B, PlGF (placental growth factor), VEGF-A, VEGF-B, PlGF (Placental Growth Factor).

Targets

VEGF (Vascular Endothelial Growth Factor) · VEGF-A, VEGF-B, PlGF (placental growth factor) · VEGF-A, VEGF-B, PlGF (Placental Growth Factor) · VEGF (vascular endothelial growth factor) · VEGF165 (Vascular Endothelial Growth Factor) · VEGF-A · VEGF-A (Vascular Endothelial Growth Factor A) · VEGF165 (vascular endothelial growth factor) · VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component) · VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors

Marketed (22)

• Intravitreal Bevacizumab IVB · Khyber Teaching Hospital · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.
• Aflibercept Intravitreous Injection · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endothelial cell receptors and reducing abnormal blood vessel growth in the eye.
• Bevacizumab-awwb · Amgen · Oncology
  Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.
• Aflibercept (Eylea) · Ahmad Zeeshan Jamil · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their pro-angiogenic signaling.
• Bevacizumab (Bev) · Eli Lilly and Company · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• Intravitreal injection of bevacizumab · Barnes Retina Institute · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.
• Macugen (Pegaptanib Sodium) · Retina Institute of Hawaii · Ophthalmology
  Pegaptanib is an aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.
• Bevacizumab (Avastin®) · Hanny Al-Samkari, MD · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors need to grow.
• Ziv aflibercept · Marashi Eye Clinic · Ophthalmology
  Ziv-aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor, binding and sequestering vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit neovascularization.
• Ranibizumab and laser · Fukushima Medical University · Ophthalmology
  Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina, while laser photocoagulation thermally destroys abnormal retinal tissue.
• Aflibercept Injection [Eylea] · Caregen Co. Ltd. · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.
• intravitreal injection with ranibizumab · University Hospital Muenster · Ophthalmology
  Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.
• intravitreal ranibizumab injections · Hospital Regional de São José - Dr. Homero de Miranda Gomes · Ophthalmology
  Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.
• pegaptanib sodium injection · Bausch & Lomb Incorporated · Ophthalmology
  Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.
• aflibercept + FOLFIRI · CR-CSSS Champlain-Charles-Le Moyne · Oncology
  Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan.
• Intravitreal Aflibercept Injection · Ophthalmic Consultants of Boston · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endogenous receptors and reducing abnormal blood vessel growth in the eye.
• intravitreal Anti-VEGF injection · Seoul National University Bundang Hospital · Ophthalmology
  Intravitreal anti-VEGF injection blocks vascular endothelial growth factor to inhibit abnormal blood vessel growth in the eye.
• Lucentis (Treat and extend) · Retinal Consultants of Arizona · Ophthalmology
  Lucentis (ranibizumab) blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina.
• Intravitreal bevacizumab · University of Sao Paulo · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.
• Rescue Intravitreal Aflibercept Injection · Southeast Retina Center, Georgia · Ophthalmology
  Aflibercept is a recombinant fusion protein that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the retina.
• anti-VEGF agent · Medical University of Vienna · Oncology, Ophthalmology
  Anti-VEGF agents block vascular endothelial growth factor signaling to inhibit abnormal blood vessel formation and reduce tumor angiogenesis.
• Subconjunctival Bevacizumab · Grewal Eye Institute · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.

Phase 3 pipeline (48)

• Bevacizumab as Avastin · Mylan Pharmaceuticals Inc · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• MYL-1701P, a proposed biosimilar to Eylea · Mylan Pharmaceuticals Inc · Ophthalmology
  MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.
• Deferred aflibercept · Jaeb Center for Health Research · Ophthalmology / Oncology
  Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), binding and neutralizing these pro-angiogenic factors.
• QL1101 · Qilu Pharmaceutical Co., Ltd. · Oncology
  QL1101 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• EU Avastin® · Bio-Thera Solutions · Oncology
  Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation and slow cancer growth.
• Bevacizumab as MYL-1402O · Mylan Pharmaceuticals Inc · Oncology
  MYL-1402O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Bevacizumab control · Institut de Recherches Internationales Servier · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.
• Aflibercept-mFOLFIRI3 · Hôpital Franco-Britannique-Fondation Cognacq-Jay · Oncology
  Aflibercept-mFOLFIRI3 is a combination regimen that pairs aflibercept (a VEGF trap) with modified FOLFIRI chemotherapy to inhibit angiogenesis while delivering cytotoxic chemotherapy.
• rhuFab V2 (ranibizumab) · Genentech, Inc. · Ophthalmology
  Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A).
• atezolizumab + avastin + platinum-based chemotherapy · ARCAGY/ GINECO GROUP · Oncology
  This combination uses an immune checkpoint inhibitor to block PD-L1, an anti-angiogenic monoclonal antibody to inhibit VEGF-mediated tumor blood vessel formation, and platinum-based chemotherapy to directly damage tumor DNA.
• Bevacizumab experimental · Institut de Recherches Internationales Servier · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.
• Arm A: FOLFIRI or FOLFOX + Bevacizumab · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Oncology
  FOLFIRI or FOLFOX chemotherapy regimens combined with bevacizumab inhibit tumor cell division and angiogenesis to treat colorectal cancer.
• Gentuximab Injection · Changchun GeneScience Pharmaceutical Co., Ltd. · Oncology
  Gentuximab is a monoclonal antibody that targets and inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis and blood vessel formation.
• EU-approved Avastin® · mAbxience Research S.L. · Oncology
  Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• Atezolizumab & Bevacizumab · IRCCS Azienda Ospedaliero-Universitaria di Bologna · Oncology
  Atezolizumab blocks PD-L1 to restore anti-tumor immunity, while bevacizumab inhibits VEGF to reduce tumor angiogenesis, together enhancing immune-mediated tumor control.
• HLX04 · Shanghai Henlius Biotech · Oncology
  HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• Aflibercept (Regeneron, USA) · Cinnagen · Oncology, Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting angiogenesis and vascular permeability.
• EU-sourced Avastin® · Cipla BioTec Pvt. Ltd. · Oncology
  Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• Subconjunctival Avastin · Vanak Eye Surgery Center · Ophthalmology
  Avastin (bevacizumab) inhibits vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel formation and leakage in the eye.
• ABP 206 · Amgen · Oncology
  ABP 206 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Prompt aflibercept · Jaeb Center for Health Research · Oncology, Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit angiogenesis.
• China-approved Bevacizumab · Zhejiang Teruisi Pharmaceutical Inc. · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.
• Eylea HD (aflibercept HD) · Alvotech Swiss AG · Ophthalmology
  Eylea HD is a high-dose formulation of aflibercept, a VEGF trap that binds and inhibits vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.
• VEGF Trap-Eye (BAY86-5321) · Bayer · Ophthalmology
  VEGF Trap-Eye is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel growth in the eye.
• Ramucirumab DP (IMC-1121B) · Eli Lilly and Company · Oncology
  Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.
• CT-P51 · Celltrion · Oncology
  CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Avastin intravitreal injection · Ophthalmological Association Edelweiss · Ophthalmology
  Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.
• AVT04 · Alvotech Swiss AG · Oncology
  AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Bevazizumab intravitreal injection · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.
• FKB238 (bevacizumab) · Centus Biotherapeutics Limited · Oncology
  FKB238 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• bevacizumab, erlotinib · Swiss Cancer Institute · Oncology
  Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).
• OCS-01 · Oculis · Ophthalmology
  OCS-01 is an anti-vascular endothelial growth factor (VEGF) inhibitor.
• Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab · Lee's Pharmaceutical Limited · Oncology
  Socazolimab is a PD-1 inhibitor monoclonal antibody, while Bevacizumab is a VEGF inhibitor monoclonal antibody. Paclitaxel is a microtubule inhibitor, and cisplatin/carboplatin are platinum-based DNA crosslinking agents.
• HLX04-O · Shanghai Henlius Biotech · Oncology
  HLX04-O is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• HLX04, a bevacizumab biosimilar · Shanghai Henlius Biotech · Oncology
  HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• SB8 · Samsung Bioepis Co., Ltd. · Oncology
  SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Bevacizumab-Pfizer · Pfizer · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• Eylea® (Aflibercept) · Alvotech Swiss AG · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.
• Anti-VEGF Therapy · Hoffmann-La Roche · Oncology, Ophthalmology
  Anti-VEGF therapy blocks vascular endothelial growth factor (VEGF), a key signaling protein that promotes abnormal blood vessel formation in tumors and certain eye diseases.
• Eylea® Solution for intravitreal injection · Rophibio, Inc. · Ophthalmology
  Eylea (aflibercept) binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.

Phase 2 pipeline (5)

• Bevacizumab and FOLFIRI · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente · Oncology
  Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor.
• Capecitabine and Bevacizumab · South Eastern European Research Oncology Group · Oncology
  Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.
• Aflibercept intravitreal injection · Innostellar Biotherapeutics Co.,Ltd · Ophthalmology
  Aflibercept binds to vascular endothelial growth factors (VEGFs) and placental growth factor (PlGF), preventing their interaction with VEGF receptors and thus inhibiting angiogenesis and vascular permeability.
• Aatezolizumab plus Bevacizumab · Tae Won Kim · Oncology
  Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy.
• Intravitreal injection of KH902 · Chengdu Kanghong Biotech Co., Ltd. · Ophthalmology
  KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.

Phase 1 pipeline (1)

• AAV2-sFLT01 · Genzyme, a Sanofi Company · Oncology
  VEGF inhibitor

Patent intelligence

• vegf inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates